Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .
Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
OBJECTIVES We investigated whether the effect of bezafibrate on  progression of coronary atherosclerosis  in the BEzafibrate Coronary Atherosclerosis Intervention Trial ( BECAIT ) was related to insulin-like growth factor (IGF)-I and glucose-insulin homeostasis . BACKGROUND BECAIT , the first double-blind , placebo-controlled , r and omized , serial angiographic trial of a fibrate compound , demonstrated that progression of focal coronary atherosclerosis in young patients after infa rct ion could be retarded by bezafibrate treatment . METHODS The treatment effects on serum concentrations of IGF-I and insulin-like growth factor binding protein (IGFBP)-1 , as well as on basal and postload glucose and insulin levels , were examined , and on-trial determinations were related to the angiographic outcome measurements . RESULTS Bezafibrate treatment result ed in a significant reduction of serum IGF-I levels , both at two and five years , and on-trial serum IGF-I levels were directly related to changes in both minimal lumen diameter ( r = 0.25 , p < 0.05 ) and mean segment diameter ( r = 0.29 , p < 0.05 ) . In contrast , none of the available indexes of insulin resistance ( homeostasis model assessment estimate , basal and postload plasma insulin concentrations and serum IGFBP-1 levels ) were related to the angiographic changes , nor were they significantly affected by bezafibrate treatment . Multiple stepwise regression analysis showed that the relation between on-trial serum IGF-I level and coronary artery disease ( CAD ) progression was independent of baseline angiographic score , age , body mass index , serum lipoprotein and plasma fibrinogen concentrations and measures of glucose-insulin homeostasis . CONCLUSIONS IGF-I could be implicated in the progression of premature CAD , and a reduction of serum IGF-I concentration could account partly for the effect of bezafibrate on progression of focal coronary atherosclerosis
Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .